2004 Annual Meeting | Evaluation and Management of Autonomic Disorders
| 02:15 PM - 02:50 PM |
Clinical and Laboratory Diagnosis of Autonomic Failure
Phillip A. Low, MD, FAAN |
|
| 02:50 PM - 03:25 PM |
Imaging the Sympathetic Nervous System
David S. Goldstein, MD, PhD |
|
| 03:25 PM - 03:40 PM |
Break
|
|
| 03:40 PM - 04:15 PM |
Autonomic Neuropathies
Roy L. Freeman, MD |
|
| 04:15 PM - 04:50 PM |
Management of Orthostatic Hypotension
Horacio C. Kaufmann, MD, FAAN |
|
| 04:50 PM - 05:25 PM |
Management of Bladder and Sexual Disorders
Jonathan Vapnek, MD |
|
| 05:25 PM - 06:00 PM |
Questions and Answers
|
| Horacio C. Kaufmann, MD, FAAN | Dr. Kaufmann has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Theravance. Dr. Kaufmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Parexel. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Kaufmann has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curasen Therapeutics. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Kaufmann has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda Pharmaceuticals. Dr. Kaufmann has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Spinger. The institution of Dr. Kaufmann has received research support from Biogen. The institution of Dr. Kaufmann has received research support from Vaxxinity. Dr. Kaufmann has received publishing royalties from a publication relating to health care. |
| Jonathan Vapnek, MD | No disclosure on file |
| No disclosure on file | |
| Roy L. Freeman, MD | Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. |
| Phillip A. Low, MD, FAAN | Dr. Low has nothing to disclose. |
| David S. Goldstein, MD, PhD | Dr. Goldstein has received publishing royalties from a publication relating to health care. |